Insider Selling: Monte Rosa Therapeutics (NASDAQ:GLUE) Insider Sells 30,000 Shares of Stock

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) insider Filip Janku sold 30,000 shares of the stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $21.42, for a total value of $642,600.00. Following the sale, the insider directly owned 59,992 shares of the company’s stock, valued at approximately $1,285,028.64. This represents a 33.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Filip Janku also recently made the following trade(s):

• On Tuesday, June 23rd, Filip Janku sold 11,845 shares of Monte Rosa Therapeutics stock. The stock was sold at an average price of $20.22, for a total transaction of $239,505.90.

Monte Rosa Therapeutics Trading Up 3.9%

Shares of NASDAQ:GLUE traded up $0.81 during midday trading on Thursday, hitting $21.66. The stock had a trading volume of 1,768,259 shares, compared to its average volume of 1,328,242. The company has a market capitalization of $1.83 billion, a PE ratio of -14.64 and a beta of 1.60. The stock has a 50 day moving average price of $18.79 and a two-hundred day moving average price of $18.58. Monte Rosa Therapeutics, Inc. has a 1 year low of $4.12 and a 1 year high of $25.77.

Monte Rosa Therapeutics (NASDAQ:GLUE) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06). The firm had revenue of $4.21 million for the quarter, compared to analyst estimates of $10.95 million. Monte Rosa Therapeutics had a negative return on equity of 40.99% and a negative net margin of 302.69%. As a group, equities analysts expect that Monte Rosa Therapeutics, Inc. will post -1.23 EPS for the current year.

Institutional Investors Weigh In On Monte Rosa Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of GLUE. State Street Corp boosted its stake in shares of Monte Rosa Therapeutics by 148.9% during the 4th quarter. State Street Corp now owns 2,107,480 shares of the company’s stock worth $33,045,000 after purchasing an additional 1,260,707 shares during the last quarter. MPM Bioimpact LLC acquired a new position in shares of Monte Rosa Therapeutics in the fourth quarter valued at approximately $18,399,000. AQR Capital Management LLC lifted its stake in shares of Monte Rosa Therapeutics by 459.4% during the second quarter. AQR Capital Management LLC now owns 1,283,942 shares of the company’s stock valued at $5,791,000 after buying an additional 1,054,406 shares during the period. Braidwell LP purchased a new position in shares of Monte Rosa Therapeutics during the fourth quarter valued at approximately $14,870,000. Finally, Vestal Point Capital LP acquired a new stake in Monte Rosa Therapeutics during the third quarter worth approximately $5,928,000. 79.96% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

GLUE has been the subject of a number of analyst reports. Weiss Ratings raised Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a research note on Monday, May 11th. JPMorgan Chase & Co. upped their price objective on Monte Rosa Therapeutics from $30.00 to $31.00 and gave the stock an “overweight” rating in a report on Monday, May 11th. Wall Street Zen cut Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Guggenheim reduced their target price on Monte Rosa Therapeutics from $34.00 to $30.00 and set a “buy” rating for the company in a report on Wednesday, March 18th. Finally, Wells Fargo & Company decreased their target price on shares of Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 18th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $32.50.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.